ProMIS Neurosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
47.8%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$7.36next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Completion of 12-Month Dosing for PRECISE-AD Phase 1b Trial | 31 Dec 2026 |
| Unblinded 12-Month Top-Line Data Release | 31 Jan 2027 |
Monitoring Framework
Key Performance Indicators
PRECISE-AD Phase 1b Trial Enrollment Quarterly144.0
Cash and Cash Equivalents Quarterly63.9MTarget: Sufficient to fund operations through 2027
Watch Items
- Blinded 6-Month Interim Analysis of PRECISE-AD Phase 1b TrialTrigger: Early Q3 2026Action: Evaluate aggregate safety data (specifically ARIA incidence) and qualitative biomarker trends across all study participants.
- Unblinded 12-Month Top-Line Data of PRECISE-AD Phase 1b TrialTrigger: Early 2027Action: Analyze comprehensive safety, biomarker, and clinical outcomes by treatment group to validate PMN310's selective targeting approach.
Research as of 20 Jun 2026